整合素α6介导急性淋巴细胞B细胞白血病的耐药
本文研究整合素α6在急性淋巴细胞白血病(ALL)耐药中的作用。体外实验显示抗人α6阻断抗体P5G10可诱导原代ALL细胞凋亡,并使其对化疗或酪氨酸激酶抑制敏感;在小鼠BCR-ABL1阳性B细胞ALL模型中条件性敲除α6可致ALL细胞凋亡,体内敲除α6联合TKI比单用TKI(尼洛替尼)更有效清除ALL;蛋白组学提示α6缺失伴随Src信号改变。
要点
- 抗α6阻断抗体P5G10在体外诱导原代ALL细胞凋亡并增强化疗敏感性
- α6缺失的鼠ALL细胞发生凋亡,体内敲除α6联合TKI优于单用尼洛替尼
- α6缺失伴Src信号改变,提示α6是ALL潜在治疗靶点
核心结论
- 整合素α6介导ALL的黏附介导耐药,可作为ALL新的治疗靶点。
研究设计与样本
- 体外用抗人α6阻断抗体P5G10处理原代ALL细胞;使用小鼠BCR-ABL1阳性B细胞ALL细胞的条件性α6敲除模型;并进行蛋白组学分析。
主要发现
- P5G10在体外诱导原代ALL细胞凋亡,并使其在体外和体内对化疗或酪氨酸激酶抑制敏感。
- α6缺陷的鼠ALL细胞发生凋亡;体内敲除α6联合TKI比单用尼洛替尼更有效清除ALL。
- 鼠ALL中α6缺失与Src信号改变相关,包括磷酸化Lyn(pTyr507)和Fyn(pTyr530)上调。
临床怎么用
- 提示α6可作为ALL耐药干预的候选靶点,联合TKI策略值得进一步转化研究。
局限性
- 证据主要来自体外原代细胞和小鼠模型,尚缺乏人体临床数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Resistance to multimodal chemotherapy continues to limit the prognosis of acute lymphoblastic leukemia (ALL). This occurs in part through a process called adhesion-mediated drug resistance, which depends on ALL cell adhesion to the stroma through adhesion molecules, including integrins. Integrin α6 has been implicated in minimal residual disease in ALL and in the migration of ALL cells to the central nervous system. However, it has not been evaluated in the context of chemotherapeutic resistance. Here, we show that the anti-human α6-blocking Ab P5G10 induces apoptosis in primary ALL cells in vitro and sensitizes primary ALL cells to chemotherapy or tyrosine kinase inhibition in vitro and in vivo. We further analyzed the underlying mechanism of α6-associated apoptosis using a conditional knockout model of α6 in murine BCR-ABL1+ B-cell ALL cells and showed that α6-deficient ALL cells underwent apoptosis. In vivo deletion of α6 in combination with tyrosine kinase inhibitor (TKI) treatment was more effective in eradicating ALL than treatment with a TKI (nilotinib) alone. Proteomic analysis revealed that α6 deletion in murine ALL was associated with changes in Src signaling, including the upregulation of phosphorylated Lyn (pTyr507) and Fyn (pTyr530). Thus, our data support α6 as a novel therapeutic target for ALL.
引用
- Gang EJ, Kim HN, Hsieh YT, et al. Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia. Blood. 2020. PMID: 32219444. doi:10.1182/blood.2019001417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。